Skip to main content
. 2012 Jun 1;6(4):437–444. doi: 10.1016/j.molonc.2012.05.003

Table 2.

Paclitaxel plus lapatinib‐treated patients with HER2‐positive disease (N = 16). On‐treatment week 9 serum samples. OS prediction

Outcome as predicted by metabolomics Predictive accuracy
Short OS Long OS
Actual outcome Short OS 73.0% 27.0%
Long OS 15.6% 84.4% 78.0%